Ipamorelin half life isn’t a countdown to feeling better.
Two hours is easy to remember. What matters is what those two hours measured—and what they didn’t.

Half of the concentration, not all of the drug
Half-life describes a drop in blood concentration. It isn’t the time until the drug vanishes, and it isn’t the length of a benefit.
Gobburu and colleagues studied healthy men receiving infusions into a vein. They estimated a terminal half-life near two hours. “Terminal” means the later part of the decline in blood levels, rather than every stage of the drug’s journey.
During that phase, one half-life means the concentration has fallen by half. It hasn’t reached zero. This is a way to describe the study’s measurements, not a blood test on you or a forecast of your own response.
The estimate needs its setting attached: healthy men, an infusion into a vein and a measured fall in concentration.
The hormone has a different clock
Ipamorelin prompts growth hormone release. The drug’s blood level and the body’s hormone response are two things researchers can measure separately.
The growth hormone response in those volunteers peaked at about forty minutes. That doesn’t contradict the two-hour drug half-life. One number describes the hormone response; the other describes how Ipamorelin’s concentration fell later.
Neither tells us when someone will sleep better or recover faster. Those would need studies measuring sleep or recovery. A hormone can change in a blood sample without the experiment showing an improvement that a person would notice.
Read how long Ipamorelin takes to work for the difference between a response and a benefit.
Under the skin is a different route
An infusion puts a drug straight into a vein. An injection under the skin adds an absorption step before the drug reaches the blood.
FDA’s 2024 assessment found a gap for the proposed under-skin route: no human data on the drug’s blood levels or hormone response. So the vein study can’t supply that missing answer. A familiar half-life figure doesn’t fix the gap.
It also can’t tell anyone when to repeat a dose. FDA’s warnings about possible immune reactions and unstudied injection routes remain. A short exposure doesn’t establish that repeated use is safe, or that a particular preparation has the right quality.
Our study-dose page explains what researchers used. A half-life alone can’t choose an amount, frequency or treatment length.